DrugPatentWatch Database Preview
Drugs in Development Information for Tegobuvir
Drug Development Status for Tegobuvir: Sponsors, patents, clinical trial progress
Tegobuvir is an investigational drug.
There have been 5 clinical trials for Tegobuvir.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis A. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
There are twenty-four US patents protecting this investigational drug and three hundred and eighty-three international patents.
Summary for Tegobuvir
| US Patents | 24 |
| International Patents | 383 |
| US Patent Applications | 45 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-05-01) |
| Vendors | 33 |
Recent Clinical Trials for Tegobuvir
| Title | Sponsor | Phase |
|---|---|---|
| GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
| GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
| Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Tegobuvir
Top disease conditions for Tegobuvir
Top clinical trial sponsors for Tegobuvir
US Patents for Tegobuvir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegobuvir | See Pricing | Method for treating HCV | AbbVie Inc. (North Chicago, IL) | See Pricing |
| Tegobuvir | See Pricing | Pyridazine compound and use thereof | Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AU) | See Pricing |
| Tegobuvir | See Pricing | Pyridazine compound and use thereof | Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AT) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegobuvir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegobuvir | Australia | 2014239563 | 2033-03-14 | See Pricing |
| Tegobuvir | Australia | 2015240754 | 2033-03-14 | See Pricing |
| Tegobuvir | Australia | 2016202823 | 2033-03-14 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
